Regardless of the improved application of traditional synthetic DMARDs (csDMARDs) and the increasing number of accepted biologic DMARDs (bDMARDs) for the treatment of RA, such as five TNF inhibitors, two IL-6 inhibitors, an IL-1 inhibitor, two anti-CD20 mAbs, and a CTLA4 inhibitor, an evident, unresolved need stands in the management of RA patients as recovery can be obtained in less than half of patients [96,97]. This evidence concerns the gene IL6 and rheumatoid arthritis.